No Picture
News

Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback

After disappointing Phase III readouts all but decimated Roche’s expectations for etrolizumab as an ulcerative colitis treatment, the pharma giant is burying the program in its quarterly cleanup ritual.
Roche noted the change in its Q3 update, where it… […]

No Picture
News

Roche writes off ulcerative colitis portion of etrolizumab program, days after dissecting PhIII setback

After disappointing Phase III readouts all but decimated Roche’s expectations for etrolizumab as an ulcerative colitis treatment, the pharma giant is burying the program in its quarterly cleanup ritual.
Roche noted the change in its Q3 update, where it… […]

No Picture
News

Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID-19

– Lambda significantly accelerated viral decline- Viral clearance highly correlated with baseline viral loads- All Lambda-treated patients were below the infectivity threshold by Day 7

PALO ALTO, Calif., Oct. 15, 2020 /PRNewswire/ — Eiger BioPha… […]

No Picture
News

Gemini Therapeutics and FS Development Corp. Announce Merger Agreement Creating Publicly Listed Precision Medicine Company Focused on Age-Related Macular Degeneration

CAMBRIDGE, Mass. & SAN FRANCISCO–(BUSINESS WIRE)–Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), and FS Development Corp. (Nasdaq: F… […]

No Picture
News

Kezar Life Sciences to Present at Four Upcoming Virtual Medical and Scientific Conferences

SAN FRANCISCO–(BUSINESS WIRE)–Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced six presentations during fou… […]

No Picture
News

Apexigen’s APX005M Granted Orphan Drug Designations for the Treatment of Esophageal and Gastroesophageal Junction Cancer and for the Treatment of Pancreatic Cancer

SAN CARLOS, Calif., Oct. 15, 2020 /PRNewswire/ — Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, announced today that the U.S. Food and Drug Ad… […]